SA
RGEN icon

Strategic Advocates’s Repligen RGEN Stock Holding History

Strategic Advocates’s Portfolio RGEN Stock Details RGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$333 – 528
2025
Q4 		$333 Hold
2
– – ﹤0.01% 568
2025
Q3 		$267 Buy
+2
New +$243 ﹤0.01% 553

Other funds holding RGEN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Strategic Advocates's RGEN Position: Q1 2026 in Review

Strategic Advocates sold out of Repligen (RGEN) in Q1 2026, closing a stake of 2 shares — an estimated $333 sold.

Strategic Advocates first reported a position in RGEN in Q3 2025 and held it in 2 quarters. The position peaked at $333 in Q4 2025. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

  • Strategic Advocates reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
  • Strategic Advocates sold 2 Repligen shares in Q1 2026, an estimated $333.
  • Strategic Advocates first reported a position in Repligen in Q3 2025 and held it in 2 quarters.
  • Strategic Advocates's Repligen position peaked at $333 in Q4 2025.
  • 441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.